The quick answer: the cited studies do not establish the safety or benefit of the combination. One reason people ask is that they want to keep muscle while losing weight, and sermorelin hasn't been shown to build muscle. If you still want both, the decision belongs with one prescriber who sees everything you take.
One is an approved weekly weight drug; the other is a compounded hormone signal
Tirzepatide is a once-weekly injection that acts on two gut-hormone receptors, GIP and GLP-1. It's FDA-approved as Zepbound for weight reduction and for obstructive sleep apnea in adults with obesity [1], and as Mounjaro for type 2 diabetes and major cardiovascular event risk reduction in high-risk adults with type 2 diabetes [2].
Sermorelin is a compounded copy of part of growth-hormone-releasing hormone. It signals the pituitary to release growth hormone. It isn't currently FDA-approved: the brand Geref lost its approvals in 2009, and FDA said in 2013 that wasn't for safety or effectiveness reasons [5].
| Tirzepatide | Sermorelin | |
|---|---|---|
| FDA status | Approved: Zepbound (weight, sleep apnea), Mounjaro (type 2 diabetes; cardiovascular risk reduction in high-risk adults with type 2 diabetes) | Not currently approved; compounded |
| How it works | GIP and GLP-1 receptor agonist | GHRH analog that prompts the pituitary to release growth hormone |
| Effect on blood sugar | Lowers it (label) [1] | Growth hormone can raise it; a related labeled drug warns of glucose intolerance [3] |
| Boxed warning | Thyroid C-cell tumors in rats; not for people with a personal or family history of MTC or MEN 2 | No current label |
| Combination benefit | Not established in cited studies | Not established in cited studies |
| Forms | Weekly injection: pens or vials (label) | Compounded injection, dissolving tablet, lozenge or nasal spray, by program |
The cited evidence does not establish the combination
The clinical sources cited here do not establish the safety or benefit of taking sermorelin and tirzepatide together. Ask for the clinical evidence behind a safety claim or a schedule for spacing them; evidence on either drug alone does not establish the pair.
Neither drug's documents flag the other. The tirzepatide labels don't mention sermorelin, growth-hormone-releasing drugs or growth hormone at all [1] [2]. Sermorelin has no current label to check. Silence isn't a green light. It does not establish the pair's interaction profile.
Blood sugar is the open question: one lowers it, the other can raise it
Growth hormone can impair glucose regulation. Tesamorelin, the one GHRH analog with a current US label, warns of glucose intolerance. In its trials, 5% of patients developed a raised HbA1c, against 1% on placebo [3]. That's a related drug, not sermorelin, but it's why prescribers watch glucose when a growth-hormone drug is added.
Tirzepatide pulls the other way. The label says it lowers blood glucose and advises considering a lower dose of insulin or sulfonylureas to reduce the risk of low blood sugar [1]. Low blood sugar has also been reported in adults without type 2 diabetes on Zepbound.
In the small sermorelin study of older men, six weeks didn't change glucose or insulin responses on a glucose tolerance test [4]. That's 11 healthy men. It can't tell you what happens in someone on tirzepatide, or with diabetes.
The tirzepatide label flags oral medicines and blood-sugar drugs
The interactions section of the tirzepatide labels covers two things. First, insulin and insulin secretagogues such as sulfonylureas, because of the low-blood-sugar risk. Second, oral medicines:
ZEPBOUND delays gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications. Caution should be exercised when oral medications are concomitantly administered with ZEPBOUND.[1]
Some programs offer sermorelin as a lozenge or a tablet that dissolves in the mouth. The label's caution is about oral medicines in general. It doesn't say whether that covers a product absorbed in the mouth, so ask your prescriber.
The muscle-preservation claim needs direct evidence
One reason people ask is that GLP-1 weight loss includes some lean tissue, and they hope sermorelin will hold on to it. The cited evidence does not establish that benefit. In a small adult muscle study, six weeks of sermorelin didn't change muscle or fat on DEXA scans [4].
What has evidence for keeping muscle is resistance training and enough protein. If body composition is your goal, the body composition shortlist starts there. If weight and metabolic health are the main goal, see the metabolic shortlist.
Keep both prescriptions with one clinician
The provider section identifies sermorelin options. A program may also offer tirzepatide, but availability of both products does not guarantee one clinician oversees them, from the first visit to the follow-up labs.
If you're thinking about compounded tirzepatide, know the dated context. FDA decided on December 19, 2024 that the tirzepatide shortage was resolved [6]. The shortage-era windows for compounders closed in February and March 2025. For sermorelin plans, our sermorelin cost guide compares prices, and how to get sermorelin prescribed covers the intake.
Expect labs on both sides if you add sermorelin
Each drug comes with its own numbers to watch. For tirzepatide, prescribers track weight, side effects and, in people with diabetes, blood sugar. For sermorelin, IGF-1 is the usual check, before you start and at follow-up.
Ask the clinician whether baseline and follow-up tests are appropriate for your circumstances. A program that doesn't plan any labs for a growth-hormone drug added to a glucose-lowering one leaves you guessing. Ask what it plans before you agree.
Ask these before adding sermorelin to tirzepatide
- What goal would sermorelin serve that I'm not already working on?
- Which labs will you check before and after, and is IGF-1 one of them?
- Should I watch my blood sugar more closely, given my history?
- Does an oral or dissolving form of sermorelin make sense alongside tirzepatide?
- What would make us stop one or both?
Your prescriber decides doses and timing for both. Don't follow a spacing rule from a website. The cited studies do not establish one.